GC Green Cross-Mokam Research Institute Collaborates with Algenomics for Intractable Disease New Drug Development

Joint Research on New Drug Development... Exchange of Material and Human Resources

[Asia Economy Reporter Kim Ji-hee] GC Green Cross and Mokam Life Science Research Institute announced on the 11th that they have signed an agreement with Algenomics for the joint development of treatments for intractable diseases based on next-generation ribonucleic acid (RNA) platforms. They will cooperate not only in joint research for drug development but also in the exchange of physical and human resources necessary for the development process.

In the course of cooperation, Algenomics will be responsible for developing next-generation technologies applicable to rare intractable diseases based on its proprietary RNA platform. Algenomics is a new drug development company based on 'RNA editing enzymes.' Its main business is the development of gene therapies for cancer and intractable diseases.

The Mokam Research Institute has established the mechanism of disease occurrence and model research foundation. Based on the technology and research capabilities acquired through mRNA and delivery system research, it will collaborate with Algenomics to derive candidate therapeutic substances. GC Green Cross will provide resources and know-how necessary for clinical research and commercialization.

Huh Eun-cheol, CEO of GC Green Cross, said, "We will continue to seek various cooperation opportunities to meet unmet needs in the treatment of intractable diseases." Lee Sung-wook, CEO of Algenomics, also stated, "Through this collaboration, we will develop next-generation RNA technology based on our proprietary platform technology and accelerate the development of innovative therapeutics."

This content was produced with the assistance of AI translation services.